MedTrace Logo

Procedural Advantages of a Novel Drug-Eluting Coronary Stent

NCT02881216 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 814

Last updated 2016-08-29

No results posted yet for this study

Summary

This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.

Conditions

Interventions

DEVICE

Synergy Stent

Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.

DEVICE

Currently common drug-eluting stent (DES)

Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)

Sponsors & Collaborators

  • University Hospital Heidelberg

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-12-31
Completion
2016-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881216 on ClinicalTrials.gov